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Abstract.  Acute  promyelocytic  leukemia  (APL)  is  a  distinct  subtype  of  myeloid  leukemia 
characterized by t(15;17) chromosomal translocation, which involves the retinoic acid receptor
alpha (RAR-alpha). APL typically presents with a life
the introduction of all-trans retinoic acid (ATRA) for the cure of APL, fatal hemorrhages due, at 
least  in  part,  to  the  APL-associated  coagulopathy,  were  a  major  cause  of  induction  remission 
failure. The laboratory abnormalities of blood  coagul
occurrence  of  a  hypercoagulable  state.
endogenous factors expressed by the leukemic cells, including procoagulant factors, fibrinolytic 
proteins, and non-specific proteolytic enzymes. In addition, these cells have an increased capacity 
to adhere to the vascular endothelium, and to secrete inflammatory cytokines [i.e. interleukin
1beta (IL-1beta) and tumor necrosis factor (TNF
prothrombotic activities by endothelial cells and leukocytes. ATRA can interfere with each of the 
principal  hemostatic  properties  of  the  leukemic  cell,  thus  reducing
potential, in parallel to the induction of cellular d
bone marrow of APL patients receiving ATRA, and is associated with the improvement of the 
bleeding symptoms. Therapy with arsenic trioxide (ATO) also beneficially affects coagulation in 
APL. However,  early deaths  from  bleeding  still  remain a  major  problem  in  APL  and  further 
research is required in this field.
pathogenesis of the APL-associated coagulopathy and will overview the therapeutic appro
the management of this complication.
Introduction. Thrombo-hemorrhagic complications in 
patients with hematologic malignancies are as frequent 
; Open Journal System 
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Acute  promyelocytic  leukemia  (APL)  is  a  distinct  subtype  of  myeloid  leukemia 
characterized by t(15;17) chromosomal translocation, which involves the retinoic acid receptor
APL typically presents with a life-threatening hemorrhagic diathe
trans retinoic acid (ATRA) for the cure of APL, fatal hemorrhages due, at 
associated  coagulopathy,  were  a  major  cause  of  induction  remission 
aboratory abnormalities of blood  coagulation found in these patients indicate the 
occurrence  of  a  hypercoagulable  state. Major  determinants  of  the  coagulopathy  of  APL  are 
endogenous factors expressed by the leukemic cells, including procoagulant factors, fibrinolytic 
proteolytic enzymes. In addition, these cells have an increased capacity 
to adhere to the vascular endothelium, and to secrete inflammatory cytokines [i.e. interleukin
1beta) and tumor necrosis factor (TNF-alpha)], which in turn stimulate the exp
prothrombotic activities by endothelial cells and leukocytes. ATRA can interfere with each of the 
principal  hemostatic  properties  of  the  leukemic  cell,  thus  reducing the  APL  cell  procoagulant 
potential, in parallel to the induction of cellular differentiation. This effect occurs 
bone marrow of APL patients receiving ATRA, and is associated with the improvement of the 
Therapy with arsenic trioxide (ATO) also beneficially affects coagulation in 
deaths  from  bleeding  still  remain a  major  problem  in  APL  and  further 
In this review, we will summarize our current knowledge of the 
associated coagulopathy and will overview the therapeutic appro
the management of this complication.
hemorrhagic complications in 
patients with hematologic malignancies are as frequent 
as in those with solid tumors and significantly affect 
morbidity  and  mortality.
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Acute  promyelocytic  leukemia  (APL)  is  a  distinct  subtype  of  myeloid  leukemia 
characterized by t(15;17) chromosomal translocation, which involves the retinoic acid receptor-
threatening hemorrhagic diathesis. Before 
trans retinoic acid (ATRA) for the cure of APL, fatal hemorrhages due, at 
associated  coagulopathy,  were  a  major  cause  of  induction  remission 
ation found in these patients indicate the 
ajor  determinants  of  the  coagulopathy  of  APL  are 
endogenous factors expressed by the leukemic cells, including procoagulant factors, fibrinolytic 
proteolytic enzymes. In addition, these cells have an increased capacity 
to adhere to the vascular endothelium, and to secrete inflammatory cytokines [i.e. interleukin-
which in turn stimulate the expression of 
prothrombotic activities by endothelial cells and leukocytes. ATRA can interfere with each of the 
the  APL  cell  procoagulant 
ifferentiation. This effect occurs in vivo, in the 
bone marrow of APL patients receiving ATRA, and is associated with the improvement of the 
Therapy with arsenic trioxide (ATO) also beneficially affects coagulation in 
deaths  from  bleeding  still  remain a  major  problem  in  APL  and  further 
In this review, we will summarize our current knowledge of the 
associated coagulopathy and will overview the therapeutic approaches for 
with solid tumors and significantly affect 
morbidity  and  mortality.
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thrombosis  and  bleeding  manifestations  may  occur 
concomitantly  as  a  part  of  the  same  thrombo-
hemorrhagic  syndrome  (THS).
2-4 Furthermore,  a 
hypercoagulable state is present in virtually all of these 
patients,  even  without  clinical  manifestations.  The 
pathogenesis of hypercoagulability is complex, and a 
central  role  is  played  by  the  fundamental  molecular 
changes  of  the  leukemic  cells,  which  overexpress 
procoagulant  factors,  as  well  as  adhesion  molecules 
and  cytokines  capable  of  inducing  procoagulant 
changes  in  the  vascular  wall  and  of  stimulating 
multiple cellular interactions. Recent molecular studies 
in  experimental  models  of  human  tumors  have 
demonstrated  for  the  first  time  that  oncogene  and 
repressor  gene-mediated  neoplastic  transformation 
induces activation of blood coagulation. Similarly, in 
cells from patients with acute promyelocytic leukemia 
(APL) the t(15;17) chromosomal translocation induces 
hyperexpression of tissue factor (TF) and renders the 
patient hypercoagulable.
5 Patients with acute leukemias 
very  often  present  with  a  range  of  laboratory 
abnormalities  consistent  with  the  diagnosis  of 
disseminated  intravascular  coagulation  (DIC)  and  a 
variety  of  clinical  manifestations,  ranging  from 
localized venous or arterial thrombosis to diffuse life-
threatening  bleeding.  The  incidence  of  these 
complications varies according to the type of leukemia 
and  to  the  phase of treatment.  In patients  with  APL 
hemorrhage  is  usually  predominant,
6 and  worsens 
during induction chemotherapy when large volumes of 
tumor cells are being destroyed rapidly. The presence 
of the coagulopathy is a significant risk factor for early 
hemorrhagic death in  APL patients,  and remains the 
most  important  cause  of  death  during  the  induction 
therapy in these patients.
7
In recent years, DIC complicating the presentation 
of  APL  has  received  new  interest,  due  to  several 
advances  in  translational  research,  including:  (1) 
enhanced  understanding  of  the  biology of  APL;  (2) 
greater  sensitivity  of  diagnostic  tests  for  subclinical 
DIC;  and  (3)  development  of  new  therapies  for 
remission  induction,  including  all-trans-retinoic  acid 
(ATRA)  and  Arsenic  Trioxide  (ATO).  ATRA 
promotes  the  terminal  differentiation  of  leukemic 
promyelocytes and ATRA-induced remission of APL 
is  accompanied  by  the  prompt  improvement  of  the 
coagulopathy of this disease.
8 ATO also induces t he 
molecular remission of APL and a simultaneous rapid 
resolution  of  the  related  coagulopathy.  The 
combination therapy of ATRA and ATO is effective in 
inducing APL remission in newly diagnosed patients, 
and  may  provide  an  alternative  to 
ATRA+chemotherapy in  this disease, with less toxic 
effects.
9 One  mechanism  of  ATRA  effect  on  the 
coagulopathy relies on its capacity to reduce the APL 
cell  procoagulant  activities  (PCA)  [i.e.  tissue  factor 
(TF) and cancer procoagulant (CP)]. Less information 
is available on the effects of ATO or the combination 
ATO+ATRA on the PCA of APL cells. In this review 
we  will  focus  on  the  pathogenesis  and  proposed 
treatment of the THS occurring in APL, with particular 
attention  to  the  effects  of  ATRA  and  ATO  on  the 
hemostatic system.
The Clinical Features of the Coagulopathy of APL. 
APL is a distinct subtype of acute myeloid leukemia 
(AML-M3),  which  typically  presents  with  a  life-
threatening  hemorrhagic  diathesis,  the  clinical  and 
laboratory  features  of  which  are  consistent  with 
DIC.
2,10 The bleeding disorder is particularly severe in 
the  microgranular  variant  of  APL  (M3v),  which  is 
characterized by marked hyperleukocytosis.
11-12 Before 
the introduction of ATRA, APL was characterized by 
high  incidence  of  hemorrhagic  death,  due  to 
intracranial  and  pulmonary  hemorrhage,  which 
significantly  contributed  to  failure  of  remission 
induction.
13 In a retrospective multicentre study of 268 
consecutive  APL  patients,  the  overall  remission  rate 
was  62%  and  the  prevalence  of  hemorrhagic  deaths 
during  induction  therapy  was  14%.  No  significant 
difference in  the  remission rate  was  observed in  the 
groups  of  patients  that  received  heparin, 
antifibrinolytic  drugs or supportive therapy alone for 
controlling the coagulopathy.
14 The use of ATRA for 
remission induction of APL has produced a complete 
remission rate >90%, together with a reduction of early 
hemorrhagic deaths  to  2.4-6.5%.
4,15 ATRA  may 
however  increase  the  risk  for  thrombosis  in  those 
patients  with  APL  who  manifest  accelerated 
differentiation,  otherwise  known  as  the  retinoic  acid 
syndrome (RAS).
8
Thrombosis and bleeding manifestations may occur 
concomitantly  as  a  part  of  the  same  THS.
3,16
Abnormalities  of  the  blood  clotting  system  are 
consistent with the diagnosis of DIC and are observed 
in the majority of these patients. Severe DIC with life-
threatening  bleeding  involves  the  very  rapid 
consumption of coagulation factors and platelets in the 
circulation as a consequence of the massive activation 
of intravascular clotting. Thrombocytopenia, caused by 
the  replacement  of  bone  marrow  megakaryocytes  by 
leukemic  cells  and  by  the  hypoplasia  subsequent  to
traditional  chemotherapy,  is  aggravated  by  the 
consumption  of  platelets  during  clot  formation. 
Secondary  bacterial  or  viral  infections  in  these 
susceptible  hosts  may  further  complicate  the 
pathogenesis of the thrombocytopenia through a direct 
toxic effects, the generation of additional stimuli for 
activation  of  blood  coagulation  (e.g.  bacterial 
endotoxin, interleukins, etc.).Mediterr J Hematol Infect Dis 2011; 3: Open Journal System
In spite of a net increase in the rate of remission 
induction  in  patients  with  APL  and  overall 
improvement in survival, hemorrhage remains the most 
common  cause  of  induction-related  death  in  patients 
with  APL, accounting for about  5% of cases in  two 
consecutive  PETHEMA  (Programa  Español  de 
Tratamiento  de  las  Hemopatias  Malignas)  group 
studies  – PETHEMA  LPA96  and  LPA99.
7 In  these 
studies, the results of a multivariate analysis to identify 
the  pre-treatment  characteristics  predictive  of  fatal 
hemorrhage found  a  significant  role  for  the  elevated 
white blood cell count (WBC >10 x 10
9/L; P<0.0001) 
and  the  abnormal  creatinine  level  (P<0.0004).  In 
addition,  the  routine  use  of  tranexamic  prophylaxis 
(100mg/kg/d  by  continuous  infusion)  in  the  second 
study,  failed  to  alter  the  risk  of  hemorrhagic  death, 
while was associated with a trend toward a statistically 
significant increase in the thrombosis rate (6% vs. 3% 
in the LPA99 and LPA96 trial, respectively; P = 0.08 
in  multivariate  analysis).  Hemorrhagic  mortality  was 
almost exclusively due to intracranial and pulmonary 
hemorrhages. Fatal hemorrhagic events occurred from 
day 1 to  day 23 with the majority noted in  the first 
week; no lethal hemorrhages were documented beyond 
the fourth week of therapy.
A recent retrospective analysis of 771 consecutive 
patients  with  non-promyelocytic  AML  admitted  to  a 
single  institution  over  the  past  30  years  revealed  a 
similar  risk  for  hemorrhagic  death  (55/771;  7%)  but 
with improved results over the more recent past (e.g. 
16%  in  the  era  1977-1986  vs.  3%  since  1994).
17
Multivariate  analysis  identified  the  following  factors 
predicting  for  hemorrhagic  mortality  in  the  AML 
patients: (1) WBC >50 x 10
9/L, P<0.0001; (2) age > 60 
years, P=0.04; (3) de novo AML, P = 0.005.
17
Finally,  the  same  PETHEMA  database  that  was 
used for assessing hemorrhagic risk was subjected to a 
retrospective  analysis  for  thrombosis  risk  in  759 
consecutive  APL  patients.
7 An  incidence  rate  of 
thrombosis  of  5.1%  (39/759)  was  observed,  and  as 
noted above, 4 cases were associated with the use of 
tranexamic acid – 2 cases of deep vein thrombosis, 1 
case  of  hemorrhagic  skin  necrosis  and  1  of  renal 
necrosis.  In multivariate analysis, hypofibrinogenemia 
at  presentation  (<170  mg/dl)  and  the  M3-variant 
subtype  remained  from  the  univariate  analysis  as 
independent  prognostic  factors.  Thrombosis  was 
observed  to  relate  to  a  higher  induction  mortality 
(including  deaths  prior  to  the  initiation  of 
chemotherapy; 28% vs. 11%, P<0.01).
7
Hemostatic  Laboratory  Abnormalities  Of  APL
Patients.  In  APL  patients  the  most  common 
abnormalities  of  routine  clotting  tests  are: 
hypofibrinogenemia,  increased  circulating  levels  of 
fibrinogen-fibrin  degradation  products  (FDPs), 
prolonged  prothrombin  and  thrombin  time.  These 
abnormalities  are  not  typical  of  any  specific 
coagulation  defect,  but  reflect  the  interaction  of 
different  pathophysiological  processes,  as  similar 
alterations of routine clotting tests may derive from the 
activation of either coagulation, fibrinolysis and non-
specific  proteolysis  These  abnormalities  can  be 
accentuated  by  the  initiation  of  cytotoxic 
chemotherapy,  resulting  in  severe  hemorrhagic 
complications.
18 The  use  of  new  and  more  sensitive 
laboratory  assays  for  the  detection  of  coagulation 
products or enzyme inhibitor complexes confirms the 
activation of coagulation, fibrinolysis and non-specific 
proteolysis. As summarized in figure 1, plasma levels 
of markers of clotting activation, i.e. the prothrombin 
fragment  1+2  (F1+2),  thrombin–antithrombin 
complexes  (TAT)  and  fibrinopeptide  A  (FPA),  are 
elevated in the majority of patients with APL.
2,19-20 At 
the same time, high levels of FDPs and urokinase-type 
plasminogen activator (u-PA) together with low levels 
of plasminogen and alpha 2-antiplasmin are described 
and provide evidence for ongoing hyperfibrinolysis.
21-
23 Finally,  plasma  levels  of  leukocyte  elastase  and 
fibrinogen split products of elastase are also increased 
and  testify  to  the  elaboration  of  non-specific 
proteases.
24 Activation  of each  of  the  three  cascades 
(i.e. coagulation, fibrinolysis or non-specific protease) 
can  potentially  trigger  the  bleeding  complications  of 
APL.  However,  the  new  laboratory  tests  for  the 
detection of markers of hypercoagulation demonstrate 
definitively  that  thrombin  generation  and  fibrin 
formation  are  constant  events  in  these  patients.  Of 
particular interest is the detection of elevated levels of 
D-dimer,  the  lysis  product  of  stabilized  cross-linked 
fibrin. This finding provides strong evidence that the 
hyperfibrinolysis typical of patients with APL is most 
likely  secondary  to  the  activation  of  the  clotting 
system.
24-28
Some  studies  have  suggested  that  primary 
hyperfibrinolysis may be the major event leading to the 
bleeding diathesis in APL.
29-31 However, on the basis 
of the laboratory tests currently available, it is difficult 
to prove the existence of primary hyperfibrinolysis in 
APL and even more difficult to establish the role of 
excessive fibrinolysis in triggering severe hemorrhage. 
In fact, while reactive, or secondary, hyperfibrinolysis, 
in  response  to  clotting  activation,  can  be  easily 
documented  in  patients  with  leukemia,  there  are  no 
specific  tests  that  define  primary 
hyperfibrino(geno)lysis  in  vivo.  The  findings  of 
profound  reductions  of  alpha  2-antiplasmin  and 
plasminogen levels, which can be corrected with the 
therapeutic  use  of  antifibrinolytic  agents,
29-30 do  not 
allow the distinction between primary and secondary Mediterr J Hematol Infect Dis 2011; 3: Open Journal System
Figure 1. Laboratories abnormalities of hemostasis in APL patients.
hyperfibrinolysis.  Tapiovaara  et  al.
32 observed  that 
cells freshly isolated from the bone marrow of patients 
with APL expressed both urokinase (uPA) and tissue-
type plasminogen activator (tPA). Findings of Mennell 
and colleagues
31 showed that Annexin II, a protein with 
high  affinity for  plasminogen and  for  tPA, is  highly 
expressed by  leukemic  cells  isolated  from  APL 
patients, when compared to non-APL leukemic cells. 
They  hypothesized  that  ‘dysregulated  expression  of 
annexin  II  on  the  surface  of  circulating  APL  cells’ 
could be responsible for primary hyperfibrinolysis in 
vivo. However, these authors assessed the activation of 
the  fibrinolytic  system  in  their  patients  with  non-
specific  tests  and  demonstrated,  among  other 
abnormalities, elevated D-dimer levels in 8/10 patients. 
It is important noticing that treatment with ATRA is 
associated  with  an  improvement  in  coagulation 
parameters,  (i.e. F1+2, TAT,  FPA, and D-dimer),  as 
well  as  with  a  decrease  in  the  plasma  fibrinolytic 
potential. Indeed it iduces the synthesis of plasminogen 
activator (PA) inhibitors and inhibits the synthesis of 
annexin II, which leads to the downregulation of the 
receptor-bound  PA  activity.
24-27 Finally,  among other 
effects,  ATRA  also  regulates  the  levels  of  von 
Willebrand factor (vWF).
33
The beneficial effects of ATRA on parameters of 
coagulation, fibrinolysis and proteolysis activation are 
associated  with  improvement  in  clinical signs  of  the 
coagulopathy in the same patients. The benefits persists 
when  ATRA  is  given  in  combination  with 
chemotherapy.
24,33-34 A  study  by  Tallman  et  al.
34
confirms  the  long-term  benefit  of  induction  therapy 
with ATRA on both disease-free and overall survival in 
APL and reaffirms the negative prognostic finding of 
clinical bleeding at the time of presentation.
Pathogenesis  of  the  Coagulopathy  of  APL. 
Consideration  of  the  pathophysiology  of  the 
hypercoagulable state of APL patients is critical to the 
design of appropriate measures for intevention. Very 
recent  molecular  studies  of  experimental  models  of 
human cancer demonstrate that oncogene and repressor 
gene-mediated  neoplastic  transformation  (e.g. 
activation of  Met,  loss  of PTEN,  induction  of K-ras 
and loss of p53) activate clotting as an integral feature 
of  neoplastic  transformation.
5 Triggering  signaling 
pathways  by  one  or  more  of  these  genes  result  in 
activation  of  blood  coagulation  and  platelet  function 
and/or suppression of fibrinolysis, which in some cases 
can produce thrombosis and/or DIC in these models.
35-
37 Similar signaling pathways have been predicted to 
play a similar role in APL. In these cells, the t(15;17)
translocation, which results in the fusion of the nuclear 
retinoic  acid  receptor  (RAR-alpha)  gene  on 
chromosome 17 with part of the PML (promyelocytic 
leukemia)  gene  on  chromosome  15,  induces 
hyperexpression  of  TF,  again  linking  the  primary 
oncogenic event with induction of hypercoagulability.
8
Although  many  exogenous  factors,  including 
cytotoxic  chemotherapy  and  concomitant  infections, 
can  impair  the  normal  delicate  balance  between 
procoagulant  and  anticoagulant  forces  in  the 
hemostatic system of patients with APL, however the 
major determinants of coagulopathy in patients with Mediterr J Hematol Infect Dis 2011; 3: Open Journal System
Figure 2. Procoagulant mechanisms of APL cells.
APL are endogenous factors related to properties of the 
malignant  leukemic  cells  and  their  interactions  with 
host  defense  mechanisms.  These  properties  include 
(Figure 2):
1. the  expression  of  procoagulant  activities, 
fibrinolytic proteins, and proteolytic enzymes,
2. the release of circulating microparticles,
3. the secretion of inflammatory cytokines,
4. the expression of surface adhesion molecules.
1. Procoagulant,  fibrinolytic,  and  proteolytic 
properties. Leukemic cells isolated from APL patients 
and  the  NB4  cell  line,  the  first  human  APL  line 
containing the typical t(15;17) chromosomal balanced 
translocation,  express  high  levels  of  procoagulant 
activity (PCA), including TF and cancer procoagulant 
(CP).  They  also  provide  an  efficient  alternative  to 
platelets as a phospholipid surface for the assembly of 
the prothrombinase complex.
TF has been characterized in APL cells by several 
researchers.
38-41 Others have demonstrated that CP also 
is expressed in leukemic blasts of various phenotypes 
and  is  found  at  the  highest  levels  in  patients  with 
APL.
42 ATRA-induced APL cell differentiation in vitro
is associated with loss of the capacity to express either 
CP
43 or  TF.
44-45 Further,  both  procoagulants  are 
progressively reduced in vivo in the bone marrow cells 
of APL patients given ATRA for remission-induction 
therapy.
24 Reduction of leukemic cell PCA by ATRA 
appears to be one important mechanism involved in the 
resolution  of  the  coagulopathy.  An  in  vitro study 
demonstrated that, after ATRA treatment, CP activity 
is  down-regulated  only  in  those  NB4  cells  that  are 
sensitive to  ATRA-induced  cyto-differentiation,  and 
not in  ATRA-resistant cells that do not differentiate. 
However, TF activity was significantly reduced in all 
cell  lines  in  response  to  ATRA,  regardless  of 
sensitivity  to  ATRA-induced  differentiation.
46 TF 
expression can be down-regulated  by ATRA in  both 
APL cells and in other types of leukemic cells
47 and 
also in normally differentiated cells.
48-51 Nuclear run-on 
experiments  in  human  monocytes  and  monocytic 
leukemia cells support the concept that ATRA inhibits 
induction  of  TF  expression  at  the  level  of 
transcription,
50 but  independently  of  the  common 
transcription  factors  AP-1  or  NF-kB.
50 Zhu  et  al.
demonstrated destabilization of TF mRNA induced by 
ATRA in NB4 cells, partially dependent upon protein 
synthesis,
51 and  Raelson  and  colleagues  showed  that 
ATRA induces synthesis of a protein in NB4 cells that 
selectively degrades PML/RAR-alpha fusion protein.
52
Therefore, one or more proteins induced by ATRA in 
leukemic  cells  may  also  destabilize  TF  mRNA.
53
Furthermore,  this  group  reported  that  bone  marrow 
cells from mice transgenic for the fusion genes PLZF-
RAR-alpha or NPM-RAR-alpha express the TF gene, 
whereas the cells derived from those mice without the 
fusion gene do not express the TF gene.
54 These data 
link  directly, for  the  first time,  the  regulation  of TF 
gene  expression  in  APL  cells  with  the  malignant 
transforming events and provide strong support for the 
hypothesis that down-regulation of TF gene expression 
is a direct result of the mechanism of the ATRA effect 
on oncogene expression.
ATO, another agent effective in the cure of APL, 
including the APL resistant to ATRA also reduces TF Mediterr J Hematol Infect Dis 2011; 3: Open Journal System
expression and PCA of APL blast cells in vitro and in 
vivo.
55 ATO  exerts  dose-dependent  dual  effects  on 
APL  cells:  at  low  concentrations  (0.5  µM),  ATO 
induces  partial  differentiation  by  degrading  the 
PML/RAR-alpha  fusion  protein;  while  at  relatively 
high  concentrations  (0.5-2.0  µM),  it  triggers 
apoptosis.
56 Zhou et al. recently published the evidence 
that ATO treatment can induce rapid loss of membrane 
procoagulant activity and TF mRNA leading beneficial 
effect  on  the  related  coagulopathy  in  APL.
57-58
However, mechanisms by which ATRA or ATO lead 
to  the  rapid  resolution  of  coagulopathy  need  further 
definition.
Concerning  the  fibrinolytic  properties,  it  is  well 
known that the normal balance between profibrinolytic 
and antifibrinolytic factors is altered in APL. Several 
events  may  contribute  to  an  increased  fibrinolysis. 
Secondary fibrinolysis may occur as a response to DIC 
at  the  onset of the  disease. Leukemic  promyelocytes 
contain  both  u-PA  and  t-PA.
59-61 In  addition,  as 
previously  described,  APL  blasts  express  increased 
levels  of  annexin  II-associated  fibrinolytic  activity.
38
Additional  data suggest that retinoids induce a rapid 
increase of u-PA activity on APL cell surface, which is 
promptly down-regulated  by an  increased  production 
of PA inhibitors, including PAI-1 and PAI-2.
32 These 
mechanisms  can  contribute  to  a  reduction  of 
fibrinolytic activity in APL cells in response to ATRA. 
Recent data confirm that after induction therapy with 
either  ATRA  or  combination  of  ATRA+ATO,  the 
levels of FDP, D-dimer, plasminogen and fibrinogen 
normalize  in  2–3  weeks,  while  the  expression  of 
Annexin II in APL blast cells is downregulated and the 
production of plasmin in APL cells is reduced.
55 It has 
been  hypothesized  that  part  of  the  coagulopathy  of 
APL is related to increased proteolysis by proteases, 
such  as  elastase,  that  degrade  fibrinogen  and  other 
clotting factors.
62-63 Increased plasma levels of elastase 
are  indeed  described  in  patients  with  acute 
leukemia.
62,64 Elastase  can  degrade  fibrinogen, 
producing  a  pattern  of  FDPs  different  from  those 
produced by plasmin cleavage.
65-66 However, in an in 
vitro  study,  freshly  isolated  APL  blasts  expressed 
lower fibrinolytic and proteolytic activities compared 
to mature neutrophils.
45
The  maintenance  levels  of  coagulation  inhibitors 
antithrombin (AT) and protein C (PC) may distinguish 
the  coagulopathy  of  APL  from  typical  DIC 
complicating  other  clinical  conditions  (e.g.  sepsis). 
Although experimental DIC can occur in the presence 
of normal levels of AT, such findings are not typical in 
clinical  practice.  Of  interest,  however,  is  the 
observation by Rodeghiero and colleagues that reduced 
levels of AT and PC in patients with acute leukemia 
tend  to  occur  in  those  patients  with  hepatic 
dysfunction.  Patients  with  acute  leukemia  and  DIC 
with normal liver function in their series usually had 
normal levels of the inhibitors.
67
In  line  with  these  findings,  the  plasma  elastase 
levels are  elevated at  the time  of  diagnosis of APL, 
most likely as the result of cell degranulation and lysis. 
However,  ATRA  therapy  does  not  appear  to  affect 
these  levels.
25 Furthermore,  no  relation  has  been 
observed  between  plasma  elastase concentration  and 
the  levels  of  D-dimer  or  other  hemostatic  variables 
during treatment with ATRA. These data, together with 
the data of De Stefano et al.,
45 cast doubt on the earlier 
hypothesis  that  elastase  makes  an  important 
contribution to the bleeding disorder of patients with 
APL or other myeloid leukemias.
64
2. Procoagulant  microparticles.  Recently, 
considerable attention has been paid to TF circulating 
in  blood  in  association  with  sub-cellular  membrane 
vesicles,  so-called  plasma  microparticles  (MPs). 
Elevated levels of TF-positive MPs have been reported 
in acute leukemias.
68
MPs  are  cell-derived  membrane  fragments 
measuring 0.1–1.0 mm, originating from normal cells, 
such as platelets, blood cells and endothelial cells (EC), 
or  malignant  cells.  Soluble  or  free  TF  found  in  the 
plasma is carried by MPs and binds directly to factor 
VIIa.
69 TF-MPs also facilitate the binding of cells and 
platelets to neutrophils and monocytes via P-selectin.
50
Thus,  hypothetically,  MPs  are  involved  directly  and 
indirectly  in  activating  coagulation.  In  APL,  the 
leukemic  promyelocytes  express  a  high  level  of  TF, 
and,  as  a  consequence  the  MPs  derived  from  the 
leukemic cells also carry TF. Thus the populations of 
TF-bearing MPs in  APL plasma are  correspondingly 
increased.  In  APL  patients,  at  onset  of  disease, 
circulating  MPs  are  mostly  from  the  APL 
promyelocytes.  During  ATRA  treatment,  the 
population of promyelocytes decreases and the platelet 
counts return to normal and therefore the number of 
MPs  decreases.
70 Other  relevant  MPs-bound 
hemostatic proteins, such as tPA, PAI-1 and annexin II, 
have  been  found  in  the  plasma  of  APL  patients. 
However,  more  studies  are  needed  to  verify  MPs 
significance as a prothrombotic factor in APL.
3. Cytokine  release.  Leukemic  cells  secrete 
various cytokines, including interleukin-1b (IL-1beta) 
and tumor necrosis factor (TNF-alpha).
71 An increased 
secretion of IL-1beta  has been observed in leukemic 
promyelocytes  from  patients  with  DIC  compared  to 
patients without DIC.
72 Both TNF-alpha and IL-1beta 
induce  the  expression  of  TF  and  PAI-1  by  EC  and 
down-regulate the expression of EC thrombomodulin 
(TM). TM is a membrane receptor of vascular EC with Mediterr J Hematol Infect Dis 2011; 3: Open Journal System
a potent anticoagulant function.
73 It binds and forms a 
complex  with  thrombin  to  activate  the  natural
anticoagulant  Protein  C.  Upregulation  of  the 
procoagulant  TF  with  downregulation  of  the 
anticoagulant  TM/Protein  C  system  converts  the 
normal anticoagulant endothelium into a prothrombotic 
endothelium.  ATRA  up-regulates  the  ability  of 
leukemic cells to produce cytokines. This effect should 
shift  the  balance  at  the  endothelium  to  the 
prothrombotic  side;  however,  ATRA  also  appears  to 
protect  the  endothelium  in  vitro against  the 
prothrombotic  assault  of  inflammatory  cytokines. 
ATRA prevents both the down-regulation of TM and 
the up-regulation of TF induced by TNF-alpha
48 and by 
IL-1beta  produced  by  NB4  promyelocytic  cells.
49
Therefore,  although  ATRA  increases  cytokine 
synthesis by APL cells, it also appears to protect the 
endothelium  against  the  prothrombotic  stimulus  of 
these mediators through a complex set of interactions.
4. Adhesion  molecules.  The  expression  on  the 
surface  of  tumor  cells  of  adhesion  molecules  and/or 
their counter-receptors permits the direct interaction of 
these cells with the host cells, including EC, platelets 
and  leukocytes.  The  attachment  of  leukemic  cells  to 
vascular EC is relevant to promote localized clotting 
activation  to  the  vessel  wall  and  to  start  the 
microthrombi formation.
Activation of the endothelium by IL-1beta or TNF-
alpha also leads to an increase in the expression of EC 
surface  adhesion  molecules,
74 such  as  ICAM-1  or 
VCAM-1, which among other functions, serve as the 
counter-receptors  for  leukemic  cell  membrane 
adhesion molecules (i.e. integrins, such as LFA-1 and 
Mac-1). Some cytokines mediate tumor cell adhesion 
to the endothelium and to the subendothelial matrix.
75-
76 Attachment of leukemic cells to the vessel wall via 
these adhesion molecules (with special emphasis on so-
called  junctional  adhesion  molecules  or  JAM),  with 
subsequent trans-endothelial migration represents one 
potential mechanism to explain the higher incidence of 
vascular complications in acute leukemia in association 
with high white blood cell (WBC) counts. Indeed, both 
early  mortality  and  the  so-called  retinoic  acid 
syndrome  (RAS),  which  is  characterized  by 
unexplained  fever,  weight  gain,  respiratory  distress, 
interstitial pulmonary inﬁltrates, pleural and pericardial 
effusions, episodic hypotension and acute renal failure, 
have been correlated with the de novo WBC count, as 
well  as  the  expression  of  one  or  more  adhesion 
molecules  and/or  cytokines  that  promote  cell–cell 
interaction.
77-79 Both  clinical  and  experimental 
evidence,  therefore,  supports  the  concept  that  in 
patients  with  high  WBC  counts,  leukemic  cells 
(particularly APL cells) promote both localized clotting 
activation  and  WBC  aggregation  by  adhesive 
interactions and subsequent activation of ECs.
80-81
Although ATRA increases the adhesion capacity of 
APL cells to the endothelium in vitro,
76 pre-treatment 
of  ECs  with  ATRA reverses  this  effect and  actually 
results in impaired adhesion of APL cells to ECs. This 
anti-adhesive  effect  may  be  explained  by  the  down-
regulation of EC surface-speciﬁc counter-receptors by 
ATRA.
76 Perhaps ATRA is unable to exert this same 
protective effect on the specialized endothelium of the 
lung, thus explaining the unusual features of the RAS. 
It  seems  likely  that  a  further  understanding  of  the 
pathogenesis of the RAS and its prevention, as well as 
better strategies for the treatment of the consumptive 
coagulopathy of APL, will evolve from an improved 
understanding of the biological properties of the fusion 
proteins of RAR-alpha.
82
Treatment  of  the  Coagulopathy  of  APL.  Modern 
recommendations  indicate  that  three  simultaneous 
actions  must  be  immediately  undertaken  when  a 
diagnosis of APL is suspected: (1) the start of ATRA 
therapy; (2) the administration of supportive care with 
plasma and platelet transfusions; (3) the confirmation 
of genetic diagnosis.
83-85 The mainstay of treatment of 
the coagulopathy of APL are shown in figure 3.
The  main  strategy  in  the  management  of  the
coagulopathy is early initiation of ATRA. This results 
in prompt resolution of the bleeding tendency and rapid 
normalization  of  coagulation  tests  and  ﬁbrinogen. 
Aggressive  attention  to  the  early  initiation  of 
supportive  measures  is  particularly  important  in  the 
management  of  acute  leukemia,  because  effective 
chemotherapy  often  exacerbates  the  DIC  and 
accentuates the bleeding syndrome by worsening the 
thrombocytopenia. The most important supportive tool, 
therefore, is the judicious use of platelet transfusion. 
The use of anticoagulants and antifibrinolytic agents, 
on the other hand, remains a hotly debated issue. The 
advent of ATRA treatment has ushered in a new era in 
the management of the coagulopathy of APL. Actually, 
because hemorrhagic complications can be a cause of 
death not only early during induction therapy but also 
before the diagnosis of APL, the current standard of 
care  consists  in  the  immediate  start  of  ATRA  even 
before the diagnosis of APL is confirmed at the genetic 
level. The simultaneous administration of ATRA and 
anthracycline-based  chemotherapy  is  currently 
considered the standard induction treatment in newly 
diagnosed patients with APL; while the use of ATO-
based  regimens  is  under  investigation  and  actually 
restricted to patients included in clinical trials or for 
those  in  whom  chemotherapy  is  contraindicated.
9,86
The combination therapy of ATRA+ATO is effective 
in inducing remission in newly diagnosed patients and Mediterr J Hematol Infect Dis 2011; 3: Open Journal System
Figure 3. Schematics of the current approaches to the APL coagulopathy
may provide an alternative to ATRA+chemotherapy in 
this disease.
9
Platelet Transfusions, Heparin and Antifibrinolytic 
Agents.  Consumption  of  platelets  and  coagulation 
factors causes bleeding symptoms, which interfere with 
therapy and  may  lead  to  hemorrhagic death.  Platelet 
transfusions represent an essential part of the modern 
supportive  care  for  all  patients  with  acute  leukemia, 
including  APL  patients.  Prophylactic  transfusion  of 
platelets has resulted in  a significant decrease in the 
incidence of fatal bleeding. In patients with APL, the 
bleeding  risk  and  platelet  transfusional  requirements 
remain  also  high  in  the  retinoic  acid  era.  Current 
recommendations  for  patients with  APL suggest that 
platelets should be transfused to maintain the platelet 
count  above  20  ×  10
9/L  in  patients  not  actively 
bleeding  and  above  50  ×  10
9/L  in  those  with  active 
bleeding.
8,87 Yanada ed al. observed that although most 
patients  who  developed  severe  hemorrhage  were 
receiving frequent transfusions, the targeted levels of 
platelet  count  (>30  ×  10
9/L)  and  plasma  fibrinogen 
(>150 mg/dL) were reached at the day of bleeding in 
only  71%  and  40%,  respectively  suggesting  that  for 
patients  at  high  risk  of  hemorrhage,  more  intensive 
transfusion may be beneficial.
88
The  role  of  heparin  in  the  treatment  of  the 
coagulopathy complicating acute leukemia, especially 
APL,  remains  uncertain.  Older  studies,  which  used 
unfractionated heparin (UH), were small, retrospective, 
and uncontrolled. The benefit of UH therapy has never 
been  proven  in  a  prospective  randomized  trial.  In  a 
retrospective  analysis  of  268  patients  with  acute 
leukemia, no benefit was demonstrated of UH for the 
prevention  of  early  hemorrhagic  deaths,  and  no 
increase was observed in complete remission rate, or 
overall  survival.
14 To  our  knowledge  no  systematic 
studies have been reported of the use of LMWH or any 
of the newer anticoagulants to treat the THS of APL. A 
RCT  utilizing  either  a  LMWH  or  fondaparinux 
(pentasaccharide) in an effort to reduce the remaining 
death  rate  in  APL  due  to  the  THS
89-90 would  seem 
appropriate.  Extrapolating  from  data  obtained  from 
patients  with  ET  or  PV,
91 it  would  also  not  be 
unreasonable  to  test  the  hypothesis  that  the  anti-
adhesive  properties  of  LMWHs, which  have  been 
observed to reduce the interaction of solid tumor cells 
with the endothelium in vitro, might prevent some of 
the  manifestations  of the  RAS in  APL patients  with 
high white blood cell counts.
90
The use of antiﬁbrinolytic agents such as epsilon-
aminocaproic  acid  (EACA,  Amicarw)  or  tranexamic 
acid,  and/or  protease  inhibitors,  such  as  Aprotinin 
(Trasylol)  in  the  management  of  APL  patients  with 
bleeding have been considered, based on a few small 
studies,
92-93 but no data from large-scale RCTs has been 
published. It is worth noting that an apparent increase 
in  TE  events  occurred  when  antifibrinolytic  agents 
were administered in conjunction with ATRA therapy 
in  two  studies.
94 As  mentioned  above,  in  the Mediterr J Hematol Infect Dis 2011; 3: Open Journal System
PETHEMA  group  studies  (e.g.  LPA99)  (32), 
tranexamic  acid  (100mg/kg/d)  administered  by 
continuous intravenous infusion until the platelet count 
was > 50x10
9/L, as in their previous studies, “failed to 
demonstrate  any  impact  on  haemorrhage-associated 
mortality”.
95 However, none of these agents has been 
tested  in  a  RCT,  where  control  subjects  were  not 
exposed to antifibrinolytic therapy.
However, the use of ATRA for remission induction 
has changed the natural history of APL and has helped 
to resolve the THS in most patients. While some of the 
mechanisms  by which  ATRA  regulates  the  aberrant 
hemostatic  system  in  patients  with  APL  have  been 
elucidated,
93 the  rate  of  early  hemorrhagic  deaths  in 
APL (3-10%) has not changed significantly. Additional 
efforts  to  develop  therapies  that  rapidly  correct  the 
coagulopathy  are  required,  as  noted  above.  New 
approaches  using  both  anticoagulant  and  anti-
inflammatory  drugs  should  be  considered.  As  the 
molecular  basis  for  activation  of  clotting  in 
hematologic  malignancies  becomes  better  elucidated, 
we anticipate the development of drugs that will target 
both the malignant process and the resultant THS.
Conclusions.  Coagulation  laboratory  abnormalities, 
indicating an activation of the hemostatic system, can 
be detected in virtually all patients with leukemias. The 
pathogenesis  is  complex  and  multifactorial.  A 
prominent  role  is  played  by  tumor-specific  clot-
promoting properties of leukemic cells themselves. In 
acute  leukemia,  bleeding  manifestations  prevail  over 
localized  thrombosis  of  large  vessels.  The  risk  of 
bleeding, due to thrombocytopenia and massive blood 
clotting  activation  with  coagulation  factors 
consumption,  reaches  a  maximum  in  patients  with 
APL.  The  coagulopathy  of  APL  is  characterized  by 
low fibrinogen levels, prolongation of the PT and TT, 
and  abnormal  plasma  levels  of  markers  of 
hypecoagulation,  hyperfibrinolysis  and  nonspecific 
proteolysis. Normal levels of AT and PC, coagulation 
inhibitors, in  patients with the  coagulopathy  of  APL 
cannot exclude DIC but may emphasize other features 
of the coagulopathy. This has raised some arguments 
against  DIC,  favoring  the  hypothesis  of  primary 
hyperfibrinolysis as the determinant of severe bleeding 
in  acute  leukemia.  However,  the  nearly  ubiquitous 
presence of elevated levels of fibrin D-dimer, and the 
increase  of  plasma  levels  of  markers  of  clotting 
activation (F1+ 2, TAT and FPA), strongly favors the 
hypothesis  of secondary or reactive hyperfibrinolysis 
occurring  in  response  to  activation  of  blood 
coagulation.  Bleeding  complications  in  patients  with 
APL carry a high risk for mortality and, therefore, the 
use  of  prophylactic  platelet  transfusions  is  highly 
recommended.  Although  not  discussed,  aggressive 
management  of  infections  is  also  very  important, 
because  viruses,  Gram-negative  and  Gram-positive 
organisms can contribute to the development of DIC. 
In  contrast,  the  routine  use  of  anticoagulants  and/or 
antifibrinolytic agents in the control or prevention of 
DIC cannot be recommended.
The advent of ATRA for induction and maintenance 
therapy of APL has profoundly modified the outlook 
for patients with this disease. Both ATRA and ATO 
have significantly improved and significantly reduced 
the  early  mortality  rates  from  the  management  of 
bleeding  in  most  series.  These  agents  treat  the 
underlying  disease,  therefore  they  fulfill  the 
requirements for an optimal treatment of DIC in APL.
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